Amedisys Given New $16.50 Price Target at Jefferies Group (AMED)
Investment analysts at Jefferies Group upped their target price on shares of Amedisys (NASDAQ:AMED) from $12.00 to $16.50 in a note issued to investors on Thursday. The firm currently has a “hold” rating on the stock. Jefferies Group’s price objective suggests a potential downside of 15.38% from the stock’s previous close.
Shares of Amedisys (NASDAQ:AMED) traded down 3.42% during mid-day trading on Thursday, hitting $19.49. 472,502 shares of the company’s stock traded hands. Amedisys has a 52 week low of $12.60 and a 52 week high of $20.93. The stock’s 50-day moving average is $15.61 and its 200-day moving average is $15.05. The company’s market cap is $647.7 million.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.25 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.04 by $0.21. The company had revenue of $305.00 million for the quarter, compared to the consensus estimate of $298.90 million. During the same quarter last year, the company posted $0.17 earnings per share. Amedisys’s revenue was down 3.5% compared to the same quarter last year. Analysts expect that Amedisys will post $0.16 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at RBC Capital raised their price target on shares of Amedisys from $7.00 to $10.00 in a research note on Friday, July 18th. They now have an “underperform” rating on the stock. Separately, analysts at Deutsche Bank upgraded shares of Amedisys from a “sell” rating to a “hold” rating in a research note on Monday, June 30th. They now have a $14.00 price target on the stock, up previously from $8.00. Finally, analysts at CRT Capital upgraded shares of Amedisys from a “sell” rating to a “fair value” rating in a research note on Friday, June 27th. Two research analysts have rated the stock with a sell rating and nine have assigned a hold rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $17.06.
Amedisys, Inc (NASDAQ:AMED) is a health care company focused on bringing home the continuum of care.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.